Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
about
Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Micel-Citrulline and l-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbitsThe prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trialSarpogrelate: cardiovascular and renal clinical potential.Pharmacological basis of different targets for the treatment of atherosclerosis.Neuroimmune mechanisms in patients with atopic dermatitis during chronic stressDifferent serotonergic expression in nevomelanocytic tumors.Comprehensive Proteome Profiling of Platelet Identified a Protein Profile Predictive of Responses to An Antiplatelet Agent Sarpogrelate.Suppression of high lipid diet induced by atherosclerosis sarpogrelate.Sustained-release formulation of sarpogrelate hydrochloride.Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers.Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet.Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway.Critical role of TNF inhibition in combination therapy for elderly mice with atherosclerosis.
P2860
Q28550589-8A147D8D-BB7D-41BA-B885-B6074E5DA070Q34016071-DD5F9944-4485-4935-A29B-1965E134A8C0Q34477919-55101726-9407-4E9B-A75A-A194E711499EQ35814472-149AF5AD-AC42-49DC-A093-365B39A67B4BQ36346487-B0FD862E-FE5D-4B86-856A-67925C526772Q36436778-BF386354-E7C3-4C75-BE66-A71F88F105FDQ41816980-388EC7BD-9BA0-4BB6-8FB5-C61F519B0031Q42687813-7054086A-ECF1-4E58-9204-FBEB0EA7C3E7Q42913768-00142EBF-1FF4-414B-AE78-82E8EB0262DAQ43407104-E83BB490-2269-46A1-989B-EB4ADD4C0C03Q44831865-032BBDE2-6F14-4BCA-B22D-D15648540FB6Q45951652-5C388266-FCE5-48F0-9A13-5C9D99AC7A1BQ46082607-1AAEA557-0555-4656-9775-5F11597FB2D7Q47639140-C5AE6E82-5A9A-4F0B-BA98-D6D17807BAA1Q48038255-B26C5B2F-377A-4068-8CE6-EB6325E49A39
P2860
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Sarpogrelate HCl, a selective ...... sis through a novel mechanism.
@ast
Sarpogrelate HCl, a selective ...... sis through a novel mechanism.
@en
Sarpogrelate HCl, a selective ...... sis through a novel mechanism.
@nl
type
label
Sarpogrelate HCl, a selective ...... sis through a novel mechanism.
@ast
Sarpogrelate HCl, a selective ...... sis through a novel mechanism.
@en
Sarpogrelate HCl, a selective ...... sis through a novel mechanism.
@nl
prefLabel
Sarpogrelate HCl, a selective ...... sis through a novel mechanism.
@ast
Sarpogrelate HCl, a selective ...... sis through a novel mechanism.
@en
Sarpogrelate HCl, a selective ...... sis through a novel mechanism.
@nl
P2093
P1433
P1476
Sarpogrelate HCl, a selective ...... sis through a novel mechanism.
@en
P2093
Akihisa Iguchi
Akiko Fukatsu
Daigo Sumi
Hatsuyo Kano
Hisako Matsui-Hirai
Juliet Arockia Rani P
Taku Tsunekawa
Toshio Hayashi
P356
10.1016/S0021-9150(03)00054-6
P577
2003-05-01T00:00:00Z